- Galcanezumab has a favorable safety and tolerability profile in patients with episodic migraine.
Why this matters
- Many patients are refractory to migraine prophylaxis , so it is important to always be looking for diverse and novel therapies that may work in these patients.
- 1 article suggested “cautious excitement” may be warranted for development of anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies for the prophylaxis of migraine.
- Randomized controlled study of 410 patients (galcanezumab, n=273; placebo, n=137) with episodic migraine.
- Funding: None.
- Patients in the galcanezumab group reported serious adverse events like appendicitis, Crohn’s disease, suicidal ideation, and congenital ankyloglossia (which occurred in a male infant whose father was treated with galcanezumab).
- Discontinuation as a result of adverse events was seen in 3 patients in the galcanezumab group because of abdominal pain, visual impairment, and upper limb fracture.
- Injection-site reactions reported more frequently in the galcanezumab group (P≤.05) and injection-site pain was most common injection-site adverse event (P≤.004).
- Frequency of upper respiratory tract infection and nasopharyngitis was higher in the galcanezumab group vs placebo group.
- Hypersensitivity events were seen in 3.3% of patients in the galcanezumab group vs 5.1% in placebo group.
- Short duration of the study.
Coauthored with Anand Ramanathan, PharmD